Vernal Biosciences
Venture Round in 2022
Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.
Bionter operates as a company with the purpose of revolutionizing analytical testing for the benefit of people's health.
Curi Bio provides seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues, with a focus on cardiac, musculoskeletal, and neuromuscular models for discovery, safety testing, and efficacy testing of new therapeutics. By offering drug developers an integrated platform comprising highly predictive human iPSC-derived cells and tissues and clinically-relevant data, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.
Virica is a developer of viral sensitizer technology that aims to enhance the manufacturing of viral vector therapeutic products. The company has created a product category known as Viral Sensitizers (VSE™), which includes a library of small molecules. These molecules are identified through a throughput screening process and are designed to target viral infections. Virica's customized VSE formulations aim to optimize research processes and improve production methods for viral medicine producers, facilitating the scalable and cost-effective development of effective viral therapies.
Envisagenics, Inc. is a biotechnology company headquartered in Huntington, New York, specializing in the development of RNA therapeutics. Founded in 2013, the company utilizes its proprietary SpliceCore platform to analyze RNA-seq data through advanced artificial intelligence and machine learning algorithms. This cloud-based technology aims to simplify the complexity of biomedical data, enabling researchers to identify splicing errors that contribute to genetic diseases and cancers. By accurately predicting drug targets and biomarkers, Envisagenics helps pharmaceutical companies reduce the time and costs associated with drug development. The platform is designed to accelerate the discovery of innovative therapeutic solutions and has the potential to address over 370 known human diseases caused by splicing errors. Through collaborations with biopharmaceutical partners, Envisagenics seeks to enhance the efficiency of drug-target selection and lead design, ultimately improving the therapeutic landscape for patients.
Xcell Biosciences, Inc. is a life science start-up based in San Francisco, California, founded in 2012. The company focuses on developing innovative technology to capture, grow, and analyze cancer cells directly from patient blood samples. Its proprietary systems allow for precise control of primary cell phenotype and function, which enhances the development and production of cell therapies. By optimizing the efficacy and persistence of immune cell therapies, Xcell Biosciences aims to contribute significantly to advancements in cancer treatment.
Vectron Biosolutions AS develops and markets vector technologies to biotechnology and life science industries. The company offers bacterial cloning vectors; expression vectors engineered for recombinant protein production in bacteria; customize vectors for specific applications; and recombinant proteins. It also provides protein production, vector design, and molecular engineering services to help its clients in life science research activities. Vectron Biosolutions AS was founded in 2008 and is based in Trondheim, Norway.
Alpenglow Biosciences, based in Seattle, Washington, specializes in advanced imaging technology for biological research. The company manufactures flatbed scanners designed for tissue analysis, which generate rich 3D molecular datasets. Its flagship product is an open-top light-sheet microscopy system that allows for the 3D scanning of intact biological samples, enhancing the capabilities of pathologists and researchers. Founded in 2018, Alpenglow aims to modernize pathology and improve the understanding of complex biological processes through its innovative imaging solutions.
Curi Bio provides seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues, with a focus on cardiac, musculoskeletal, and neuromuscular models for discovery, safety testing, and efficacy testing of new therapeutics. By offering drug developers an integrated platform comprising highly predictive human iPSC-derived cells and tissues and clinically-relevant data, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.
Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in the manufacture of real-time cellular activity monitors. The company focuses on accelerating drug discovery and advancing basic biological research by providing systems that enable real-time cellular analysis. Its primary customers include academic institutions and pharmaceutical companies, which utilize Lucid Scientific's technology to enhance their research and development processes.
CellFE Inc. is a San Carlos, California-based company that specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. Founded in 2017, CellFE's innovative platform employs rapid cell compressions to enhance the uptake of therapeutic molecules from the surrounding fluid, facilitating the development and manufacturing of advanced cell therapies. This technology aims to address previously inaccessible cell therapies, enabling medical researchers to transport difficult-to-deliver molecules into cells for the treatment of various disorders, ultimately improving patient outcomes.
RoosterBio, Inc. is a biotechnology company specializing in the development of mesenchymal stem cells (MSCs) for the regenerative medicine sector. Founded in 2012 and headquartered in Frederick, Maryland, RoosterBio provides human bone marrow and adipose-derived MSCs designed for tissue engineers and cell therapists. These products aim to facilitate the creation of technologies, products, and devices that incorporate living cells. The company's offerings are intended to simplify and accelerate research in regenerative medicine by addressing common challenges in stem cell research and commercialization. RoosterBio has formed strategic alliances with organizations such as Pall Corporation and Tissue Regeneration Therapeutics Inc., further enhancing its capabilities in the field.
RoosterBio, Inc. is a biotechnology company specializing in the development of mesenchymal stem cells (MSCs) for the regenerative medicine sector. Founded in 2012 and headquartered in Frederick, Maryland, RoosterBio provides human bone marrow and adipose-derived MSCs designed for tissue engineers and cell therapists. These products aim to facilitate the creation of technologies, products, and devices that incorporate living cells. The company's offerings are intended to simplify and accelerate research in regenerative medicine by addressing common challenges in stem cell research and commercialization. RoosterBio has formed strategic alliances with organizations such as Pall Corporation and Tissue Regeneration Therapeutics Inc., further enhancing its capabilities in the field.
FloDesign Sonics is changing the separations and filtration markets through a novel acoustic technology. By leveraging breakthroughs in the use of 3D acoustic standing waves, FloDesign Sonics is able to capture, separate and purify without using physical membranes, chemicals, or centrifugation. Our proprietary technology has numerous applications in a variety of markets including life sciences, oil and gas, food and beverage and industrial processing. The first commercial application is in bioprocess separations where FloDesign Sonics is applying acoustic technology to the manufacturing of life saving bio-pharmaceuticals. For more information, contact info@fdsonics.com
Envisagenics, Inc. is a biotechnology company headquartered in Huntington, New York, specializing in the development of RNA therapeutics. Founded in 2013, the company utilizes its proprietary SpliceCore platform to analyze RNA-seq data through advanced artificial intelligence and machine learning algorithms. This cloud-based technology aims to simplify the complexity of biomedical data, enabling researchers to identify splicing errors that contribute to genetic diseases and cancers. By accurately predicting drug targets and biomarkers, Envisagenics helps pharmaceutical companies reduce the time and costs associated with drug development. The platform is designed to accelerate the discovery of innovative therapeutic solutions and has the potential to address over 370 known human diseases caused by splicing errors. Through collaborations with biopharmaceutical partners, Envisagenics seeks to enhance the efficiency of drug-target selection and lead design, ultimately improving the therapeutic landscape for patients.
FloDesign Sonics is changing the separations and filtration markets through a novel acoustic technology. By leveraging breakthroughs in the use of 3D acoustic standing waves, FloDesign Sonics is able to capture, separate and purify without using physical membranes, chemicals, or centrifugation. Our proprietary technology has numerous applications in a variety of markets including life sciences, oil and gas, food and beverage and industrial processing. The first commercial application is in bioprocess separations where FloDesign Sonics is applying acoustic technology to the manufacturing of life saving bio-pharmaceuticals. For more information, contact info@fdsonics.com